| Bioactivity | vMIP-II (1-21) is a CXCR4 antagonist. vMIP-II has broad-spectrum interaction with CC and CXC chemokine receptors. vMIP-II (1-21) binds with CXCR4 with an IC50 value of 190 nM for competing with CXCR4 binding of 125I-SDF-1R[1]. |
| Invitro | vMIP-II (1-21) (0.01-10 μM) 可与趋化因子受体 CXCR4 结合[1]。vMIP-II (1-21) (25-200 μM) 抑制 CXCR4 介导 T 和双亲性 HIV-1 gp120 介导的细胞-细胞融合[1]。vMIP-II (1-21) (100 μM) 剂量依赖性地抑制的趋化活性[1]。 |
| Name | vMIP-II (1-21) |
| CAS | 265650-93-9 |
| Sequence | Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys-Cys-Cys-Leu-Gly-Tyr-Gln-Lys-Arg-Pro-Leu-Pro |
| Shortening | LGASWHRPDKCCLGYQKRPLP |
| Formula | C108H169N33O27S |
| Molar Mass | 2425.84 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
vMIP-II (1-21)
CAS: 265650-93-9 F: C108H169N33O27S W: 2425.84
vMIP-II (1-21) is a CXCR4 antagonist. vMIP-II has broad-spectrum interaction with CC and CXC chemokine receptors. vMIP-I
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.